

Bradley Merrill Thompson Mentioned in “FDA Combo Products Guidance Offers More Flexibility for Cross-Labeling”

BioWorld

January 31, 2022 | Media Coverage

Bradley Merrill Thompson, Strategic Advisor with EBG Advisors and Member of the Firm in the Health Care & Life Sciences practice at Epstein Becker Green, was mentioned in *BioWorld*, in “FDA Combo Products Guidance Offers More Flexibility for Cross-Labeling,” by Mark McCarty. (*Read the full version – subscription required.*)

Following is an excerpt:

U.S. FDA regulation of combination products has always been complicated, and a new final guidance takes up the long-standing controversy over FDA review of these applications. The final guidance makes explicit the possibility that the individual components of a cross-labeled combination product will be reviewed separately, a concession that industry saw as critical to ensure that these applications can make it through the FDA gauntlet without undue delay. ...

Representing the Combination Products Coalition (CPC), regulatory attorney Brad Thompson of Epstein Becker & Green P. C., noted in comments to the docket [that they had not finished our review of the guidance] ...

People



Bradley Merrill Thompson
Strategic Advisor
Artificial Intelligence
202-861-1817
bthompson@ebglaw.com

Focus Areas

Services

Life Sciences